Covenant Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,985
| Closed | -$231K | – | 164 |
|
|
2025
Q2 | $231K | Buy |
4,985
+33
| +0.7% | +$1.62K | 0.03% | 146 |
|
|
2025
Q1 | $302K | Buy |
4,952
+28
| +0.6% | +$1.63K | 0.07% | 137 |
|
|
2024
Q4 | $279K | Buy |
+4,924
| New | +$275K | 0.04% | 151 |
|
|
2024
Q2 | – | Sell |
-3,857
| Closed | -$209K | – | 164 |
|
|
2024
Q1 | $209K | Sell |
3,857
-12,985
| -77% | -$661K | 0.03% | 141 |
|
|
2023
Q4 | $864K | Sell |
16,842
-7,641
| -31% | -$401K | 0.16% | 92 |
|
|
2023
Q3 | $1.42M | Buy |
24,483
+113
| +0.5% | +$6.92K | 0.37% | 69 |
|
|
2023
Q2 | $1.56M | Sell |
24,370
-220
| -0.9% | -$14.8K | 0.4% | 73 |
|
|
2023
Q1 | $1.7M | Sell |
24,590
-5,192
| -17% | -$366K | 0.41% | 76 |
|
|
2022
Q4 | $2.14M | Buy |
29,782
+4,122
| +16% | +$311K | 0.51% | 61 |
|
|
2022
Q3 | $1.82M | Buy |
25,660
+555
| +2% | +$40.3K | 0.52% | 62 |
|
|
2022
Q2 | $1.93M | Buy |
25,105
+47
| +0.2% | +$3.58K | 0.61% | 57 |
|
|
2022
Q1 | $1.83M | Buy |
25,058
+19
| +0.1% | +$1.28K | 0.49% | 61 |
|
|
2021
Q4 | $1.56M | Sell |
25,039
-340
| -1% | -$19.9K | 0.41% | 59 |
|
|
2021
Q3 | $1.5M | Buy |
25,379
+60
| +0.2% | +$3.95K | 0.45% | 62 |
|
|
2021
Q2 | $1.69M | Buy |
25,319
+625
| +3% | +$40.8K | 0.5% | 55 |
|
|
2021
Q1 | $1.56M | Buy |
24,694
+234
| +1% | +$14.6K | 0.49% | 61 |
|
|
2020
Q4 | $1.52M | Sell |
24,460
-213
| -0.9% | -$13.1K | 0.5% | 57 |
|
|
2020
Q3 | $1.49M | Buy |
24,673
+22
| +0.1% | +$1.32K | 0.48% | 56 |
|
|
2020
Q2 | $1.45M | Buy |
24,651
+972
| +4% | +$58.1K | 0.32% | 61 |
|
|
2020
Q1 | $1.32M | Buy |
23,679
+1,496
| +7% | +$91.4K | 0.4% | 59 |
|
|
2019
Q4 | $1.42M | Buy |
22,183
+8
| +0% | +$458 | 0.62% | 60 |
|
|
2019
Q3 | $1.12M | Buy |
22,175
+2,969
| +15% | +$140K | 0.56% | 61 |
|
|
2019
Q2 | $871K | Buy |
19,206
+800
| +4% | +$37.3K | 0.45% | 67 |
|
|
2019
Q1 | $878K | Buy |
18,406
+1,830
| +11% | +$91.2K | 0.46% | 68 |
|
|
2018
Q4 | $1.03M | Hold |
16,576
| – | – | 0.52% | 64 |
|
|
2018
Q3 | $1.03M | Buy |
16,576
+400
| +2% | +$23.7K | 0.52% | 64 |
|
|
2018
Q2 | $895K | Buy |
16,176
+1,108
| +7% | +$59.8K | 0.48% | 68 |
|
|
2018
Q1 | $953K | Buy |
15,068
+1,439
| +11% | +$92.6K | 0.55% | 62 |
|
|
2017
Q4 | $835K | Buy |
13,629
+1,579
| +13% | +$98.8K | 0.49% | 72 |
|
|
2017
Q3 | $768K | Hold |
12,050
| – | – | 0.47% | 75 |
|
|
2017
Q2 | $671K | Sell |
12,050
-420
| -3% | -$22.9K | 0.43% | 84 |
|
|
2017
Q1 | $678K | Sell |
12,470
-7,570
| -38% | -$415K | 0.46% | 79 |
|
|
2016
Q4 | $1.17M | Buy |
+20,040
| New | +$1.1M | 0.79% | 46 |
|
Other funds holding BMY
Covenant Asset Management's BMY Position: Q3 2025 in Review
Covenant Asset Management sold out of Bristol-Myers Squibb (BMY) in Q3 2025, closing a stake of 4,985 shares — an estimated $231K sold.
Covenant Asset Management first reported a position in BMY in Q4 2016 and held it in 33 quarters. The position peaked at $2.14M in Q4 2022. 2,274 funds tracked by Wall St. Rank hold BMY as of Q3 2025.
- Covenant Asset Management reported no remaining Bristol-Myers Squibb position as of Q3 2025 after selling out during the quarter.
- Covenant Asset Management sold 4,985 Bristol-Myers Squibb shares in Q3 2025, an estimated $231K.
- Covenant Asset Management first reported a position in Bristol-Myers Squibb in Q4 2016 and held it in 33 quarters.
- Covenant Asset Management's Bristol-Myers Squibb position peaked at $2.14M in Q4 2022.
- 2,274 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.
Based on Covenant Asset Management's 13F filing for Q3 2025, filed 30 Oct 2025.